DAFTAR PUSTAKA

Abbas, A.K., Lichtman, A.H., Pillai, S., 2007. *Cellular and Molecular Immunology* Edisi 6. Philadelphia: Elsevier-Saunders Publishing.

Ahmed, S., *et al*, 2021. Evaluation of serum ferritin for prediction of severity and mortality in COVID-19-A cross sectional study, Annals of medicine and Surgery, 63, p.102163.

Aslan, A., Aslan, C., Zolbanin, N. M., Jafari, R., 2021. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management, Pneumonia, 13(1), p.1-15.

Avila-Nava, A., *et al*, 2021. Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico. Cytokine. Vol. 143, p.155543.

Banchini, F., Cattaneo, G.M., Capelli, P., 2021. Serum ferritin levels in inflammation: a retrospective comparative analysis between COVID-19 and emergency surgical non-COVID-19 patients. World J Emerg Surg 16, p.1-9.

Bhardwaj, A., *et al*, 2022. COVID-19: immunology, immunopathogenesis and potential therapies. International reviews of immunology, 41(2), p.171-206.

Booth, A., *et al*, 2021. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One, 4;16(3), p.1-30.

Bonow, R.O., Fonarow, G.C., O'Gara, P.T., Yancy, C.W., 2020. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 5(7), p.751–753.

Burhan, E., Susanto, A.D., Nasution, S.A., Ginanjar, E., Pitoyo, C.W., Susilo, A., Anwar, S., 2022. *Pedoman Tatalaksana Covid-19*. Edisi 4. Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI.

Chandrashekara, S., 2014. C-reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis. Internet Journal of Rheumatology and Clinical Immunology, 2(S1), p.1-23.

Chavez-Ocaña, S.D.C.,*et al*, 2023. Parameters to Predict the Outcome of Severe and Critical COVID-19 Patients when Admitted to the Hospital. J. Clin. Med. 12, p.1323.

Chicamy, Y.A., Safitri, A., Nindrea, R.D., 2022. Serum Ferritin Levels for the Prediction of Mortality among COVID-19 Patients in an Indonesia's National Referral Hospital, Open Access Macedonian Journal of Medical Sciences, 10(B), p.1056-1061.

Coe, C.L., *et al*, 2011. Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. Brain Behav Immun. Epub, 11, p26.

Comoglu, S., Kant, A., 2022. Does the Charlson comorbidity index help predict the risk of death in COVID-19 patients? *Northern Clinics of Istanbul*. 9(22), p.117-121.

Crichton, M.L., *et al*, 2021. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. European respiratory review, 30, p.162.

Cullis, J.O., 2018. Investigation and management of a raised serum ferritin. British journal of haematology, 181(3), p.331-340.

De Brito, R.C., Lucena, S.N,. Torres, L.C., Luna C.F., Correia, J.B., Da Silva, G.A., et al, 2016. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia. BMC Pulm Med, 16, p170.

De Roquetaillade, C., *et al*, 2021. Timing and causes of death in severe COVID-19 patients. Critical Care, 25(1), p.1-8.

Dessie, Z.G., Zewotir, T., 2021. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC infectious diseases. 21(1), p.1-28.

Dohoo, I., Martin, W., Stryhn, H., 2009. *Veterinary Epidemiologic Research*. Edisi 2. Canada : VER Inc.

Dongelmans, D.A., *et al*, 2022. Characteristics and outcome of COVID-19 patients admitted to the ICU: a nationwide cohort study on the comparison between the first and the consecutive upsurges of the second wave of the COVID-19 pandemic in the Netherland. Ann. Intensive Care 12, p.5-9.

Drummond, G.R., Vinh, A., Guzik, T.J., Sobey, C.G., 2019. Immune mechanisms of hypertension. Nat. Rev. Immunol. 19, p.517–532.

Du, R.H., *et al*, 2020. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 7;55(5):2000524, p.1-8.

Edeas, M., Saleh, J., Peyssonnaux, C., 2020. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis. International Journal of Infectious Diseases, 97, p.303-305.

Ehlting, C., Wolf, S.D., Bode, J.G., 2021. Acute-phase protein synthesis: a key feature of innate immune functions of the liver. Biological Chemistry. 402(9), p.1129–1145.

Ejaz, H., *et al*, 2020. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 13(12), p1833-1839.

El-Shabrawy, M., *et al*, 2021. Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. The Egyptian Journal of Bronchology, 15(1), p.1-7.

Feng, Y., *et al*, 2020. COVID-19 with different severities: a multicenter study of clinical features. American journal of respiratory and critical care medicine, 201(11), p.1380-1388.

Gao S.P., *et al*. Interleukin-6 genotypes and serum levels in Chinese Hui population. Int J Clin Exp Med. 2014 Sep 15;7(9), p.2851-2857.

Hadi J.M., *et al*. Investigation of Serum Ferritin for the Prediction of COVID-19 Severity and Mortality: A Cross-Sectional Study. Cureus. 2022 Nov 28;14(11):e31982.

Hirano, T., 2021. IL-6 in inflammation, autoimmunity and cancer. International immunology, 33(3), p.127-148.

Huang, I., *et al*, 2020. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic advances in respiratory disease. 14, p.1-14.

Hussain, A., *et al*, 2020. Obesity and mortality of COVID-19 Meta-analysis. Obes Res Clin Pract. 14(4), p.295-300.

Jafarzadeh, A., Nemati, M., Jafarzadeh, S., 2021. Contribution of STAT3 to the pathogenesis of COVID-19. Microbial Pathogenesis. 154:104836, p.1-9.

Kang, S., *et al*, 2020. IL-6 transsignaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proceedings of the National Academy of Sciences. 117(36), p.22351-22356.

Kaushal, K., *et al*, 2022. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. Journal of critical care. 67, p.172-181.

Kell, D.B., Pretorius, E., 2014. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 6(4), p.748–73.

Kernan, K.F., Carcillo, J.A., 2017. Hyperferritinemia and inflammation. International immunology. 29(9), p.401-409.

Klassen, *et al*, 2021. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. In Mayo Clinic Proceedings. Elsevier. Vol. 96 (5), p.1262-1275.

Krynytska, I., *et al*, 2021. COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome. Iranian Journal of Microbiology. 13(6), p.737.

Kuribayashi, T., 2018. Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in response to inflammatory stimulation in rats. Lab Anim Res. 34(2), p.80-83.

Lakbar, I., *et al*, 2020. COVID-19 gender susceptibility and outcomes: A systematic review. PLoS One. 3;15(11):e0241827, p.1-15.

Latif. M.B., *et al*, 2022. Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Transl Res. (3)241, p.83-95.

Maghfirah, A.I., 2022. Correlation of Serum Ferritin Levels and COVID-19 Severity in Makassar. Makassar: Journal of Microbiology and Immunology, Vol.4, Issue 1, p.1-5.

Magro, G., 2020. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion'of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Elsevier. 100029, p.1-7.

Mahroum, N., *et al*, 2022. Ferritin–from iron, through inflammation and autoimmunity, to COVID-19. Journal of Autoimmunity. 126:102778, p.1-11.

Mandel, M., Harari, G., Gurevich, M., Achiron, A, 2020. Cytokine prediction of mortality in COVID19 patients. Elsevier: Cytokine. 134, 155190, p.2-5.

Marimuthu, A.K., *et al*, 2021. Utility of various inflammatory markers in predicting outcomes of hospitalized patients with COVID-19 pneumonia: A single-center experience. Lung India: Official Organ of Indian Chest Society. 38(5), p.448.

Markanday, A., 2015, Acute phase reactants in infections: evidence-based review and a guide for clinicians, In Open forum infectious diseases, Oxford University Press. Volume 2, Issue 3, p.1-7.

Martins, M.P., De Oliveira, R.B., 2023. COVID-19 and Chronic Kidney Disease: A Narrative Review. Vol. 3, p.1092-1105.

Merad, M., Blish, C.A., Sallusto, F., Iwasaki, A., 2022. The immunology and immunopathology of COVID-19. Science. 375(6585), p.1122-1127.

Milenkovic M., et al, 2022. D-dimer, CRP, PCT, and IL-6 levels at admission to ICU can predict in-hospital mortality in patients with covid-19 pneumonia. Oxidative medicine and cellular longevity. Vol. 2022, p.1-9.

Moore B.J.B., June, C.H., 2020. Cytokine release syndrome in severe COVID-19. Science. 368(6490), p.473– 474.

Mosquera- Sulbaran, J.A., Pedreañez, A., Carrero, Y., Callejas, D., 2021. C-reactive protein as an effector molecule in Covid- 19 pathogenesis. Reviews in Medical Virology. 31(6), e2221, p.1-8.

Mousavizadeh, L., Ghasemi, S., 2021. Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology Immunology and Infection. 54(2), p.159-163.

Mubarak, A.R., Esa, T., Widaningsih, Y., Bahrun, U., 2021. D-dimer Analysis in COVID-19 Patients. Indonesian journal of clinical pathology and medical laboratory. 28(1), p.5–9.

Nannoni, S., De Groot R., Bell, S., Markus, H.S., 2021. Stroke in COVID-19: A systematic review and meta-analysis. Int J Stroke. 16(2), p.137-149.

Nazmi, A., Victora, C.G., 2007. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health. 17(7), p.212.

Noordhuizen, J. P., Frankena, K., Thrusfield, M. V., Graat, E. A., 2001. *Application of quantitative methods in veterinary epidemiology*. Netherlands: Wageningen Pers.

Nilsonne, G., *et al*., 2016. Diurnal Variation of Circulating Interleukin-6 in Humans: A Meta-Analysis. PLoS One. 10;11(11):e0165799, p.1-7.

Paludan, S.R., Mogensen, T.H., 2022. Innate immunological pathways in COVID-19 pathogenesis. Science Immunology, 7(67), eabm5505, p.1-20.

Peters M.J., *et al*, 2013. Circulating IL-6 concentrations and associated anthropometric and metabolic parameters in South Asian men and women in comparison to European whites. Cytokine. Vol. 61(1), p.29-32.

Pepys, M.B., Hirschfield, G.M., 2003. C-reactive protein: a critical update. The Journal of clinical investigation. 111(12), p.1805-1812.

Poudel, A., *et al*, 2021. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. Plos one. 16(8), e0256744, p.1-13.

Qeadan, F., *et al*, 2021. Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19. Viruses. Vol 13, p.419.

Rahayu, R., Winarto, W., Nasihun, T, 2022. Interleukin-6 and C-reactive Protein on Admission as Predictor of Mortality in Severe COVID-19 Patients: A Retrospective Cohort Study. Open Access Macedonian Journal of Medical Sciences. 10(B), p.227-231.

Reviono, Sari, Y., Suryawati, B., Yasa, K.P., 2022. Frequency of Interleukin-6 rs 1800796 (-572G/C) and 2069837 (intron 2A/G), TNF-α rs1800750 (-376G/A), and 1800629 (-308G/A) polymorphism in COVID-19 patients with clinical degrees in Central Java. Bali Medical Journal. 11(3), p.1364-1368.

Sandnes, M., Ulvik, R.J., Vorland, M., Reikvam, H., 2021. Hyperferritinemia a clinical overview, Journal of Clinical Medicine, 10(9), 2008, p.1-25.

Satuan Tugas Penanganan Covid 19. 2022. Coronavirus (COVID-19) Dashboard. https://covid19.go.id/. Diakses pada tanggal 21 Agustus 2022.

Sette, A., & Crotty, S., 2021. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 184(4), p.861-880.

Shakaroun, D.A., Lazar, M.H., Horowitz, J.C., Jennings, J.H., 2023. Serum ferritin as a predictor of outcomes in hospitalized patients with covid-19 pneumonia. J Intensive Care Med. Vol.38(1), p.21-26.

Singh, R., *et al*, 2022. Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression. Front Endocrinol (Lausanne). 3;13:780872, p.1-18.

Sproston, N.R., Ashworth, J.J., 2018. Role of C-reactive protein at sites of inflammation and infection. Frontiers in immunology. Vol.9, p.754.

Straat M.E., et al, 2022. Differences in inflammatory pathways between Dutch South Asians vs Dutch Europids with type 2 diabetes. The Journal of clinical endocrinology and metabolism. Vol. 108:Issue 4, p. 931–940.

Stringer, D., *et al*, 2021. The role of C-reactive protein as a prognostic marker in COVID-19, International journal of epidemiology. 50(2), p.420-429.

Sugiarto, A., Pryambodho, Imelda, M., Aditianingsih, D., 2023. Charlson comorbidity index to predict 28-day mortality in critically ill COVID-19 patients. Medical Journal of Indonesia. 1(1), p.19-25.

Sun, H., Guo, P., Zhang, L., Wang, F., 2020. Serum Interleukin-6 Concentrations and the Severity of COVID-19 Pneumonia: A Retrospective Study at a Single Center in Bengbu City, Anhui Province, China, in January and February 2020. Medical science monitor. International medical journal of experimental and clinical research. 26, e926941, p.1-6.

Susilo, A., *et al*, 2020. Coronvirus disease 2019 Tinjauan literatur terkini. Jakarta: Jurnal Penyakit Dalam Indonesia. Vol.7(1), p.45-67.

Swaroopa, D., *et al*, 2016. Association of serum interleukin-6, interleukin-8, and Acute Physiology and Chronic Health Evaluation II score with clinical outcome in patients with acute respiratory distress syndrome, Indian journal of critical care medicine : peer-reviewed. Indian Society of Critical Care Medicine. 20(9), p.518–525.

Tanaka, T., Narazaki, M., Kishimoto, T., 2014. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor perspectives in biology. 6(10), a016295, p.1-16.

Udovica, S., Müser, N., Pechlaner, A., 2022. High mortality in patients with active malignancy and severe COVID-19. Magazine of European Medical Oncology. Vol.15, p.153–160.

Vargas, J.R., *et al*, 2022. Sustained Hyperglycemia and Its Relationship with the Outcome of Hospitalized Patients with Severe COVID-19: Potential Role of *ACE2* Upregulation. J Pers Med. 12, p.805.

Vekaria, B., Overton, C., Wiśniowski, A., 2021. Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning. BMC Infect Dis 21:700, p.1-15.

Veras, F.P., *et al*, 2020. SARS-CoV-2-Triggered Neutrophil Extracellular Traps Mediate COVID-19 Pathology. J Exp Med. 7:217(12):e20201129, p.1-15.

World Health Organization (WHO), 2022. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Diakses pada tanggal 21 Agustus 2022.

Wu, M.A., *et al*, 2021. Hypoalbuminemia in COVID-19: Assessing the Hypothesis for Underlying Pulmonary Capillary Leakage. J Intern Med. Vol.289, p.861–872.

Zerbato, V., *et al*, 2022. The Impact of Serum Albumin Levels on COVID-19 Mortality. Infect Dis Rep. 20;14(3), p.278-286.

Zhan, H. *et al*, 2021. Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. Clinical and Applied Thrombosis/Hemostasis. Vol.27, p.1-10.

Zhang, L., *et al*, 2021. The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis. Epub Arch virology. 166, p.2071-2087.

Zhang, J., *et al*, 2020. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. Journal of translational medicine. 18(1), p.1-8.

Zheng, Z., *et al*, 2020. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of infection, 81(2), p.16-25.

Zhou, F., Yu, T., Du, R., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Vol.395(10229), p.1054–1062.

Zhou, Y., *et al*, 2020. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. International Journal of Infectious Diseases. Vol.99, p.47-56.